董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael J. O’Donnell | 男 | Director | 62 | 未披露 | 未持股 | 2021-03-31 |
| Remi Barbier | 男 | President, Chief Executive Officer, Chairman of the Board | 61 | 93.61万美元 | 未持股 | 2021-03-31 |
| Nadav Friedmann | 男 | Chief Medical Officer and Director | 78 | 34.50万美元 | 未持股 | 2021-03-31 |
| Robert Z. Gussin | 男 | Director | 83 | 7.59万美元 | 未持股 | 2021-03-31 |
| Patrick J. Scannon | 男 | Director | 73 | 未披露 | 未持股 | 2021-03-31 |
| Patrick J. Scannon | 男 | Director | 73 | 3.80万美元 | 未持股 | 2021-03-31 |
| Michael J. O'donnell | 男 | Director | 62 | 3.34万美元 | 未持股 | 2021-03-31 |
| Sanford R. Robertson | 男 | Director | 89 | 7.59万美元 | 未持股 | 2021-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James W. Kupiec | 男 | Chief Clinical Development Officer | 68 | 未披露 | 未持股 | 2021-03-31 |
| Remi Barbier | 男 | President, Chief Executive Officer, Chairman of the Board | 61 | 93.61万美元 | 未持股 | 2021-03-31 |
| Nadav Friedmann | 男 | Chief Medical Officer and Director | 78 | 34.50万美元 | 未持股 | 2021-03-31 |
| Eric J. Schoen | 男 | Chief Financial Officer | 52 | 25.19万美元 | 未持股 | 2021-03-31 |
董事简历
中英对照 | 中文 | 英文- Michael J. O’Donnell
-
暂无中文简介
Michael J. O’Donnell has served as a director since June 1998. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster LLP since 2011. Morrison & Foerster LLP is the Company’s corporate counsel and provides legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Previously, Mr. O’Donnell was a member of Wilson Sonsini Goodrich & Rosati. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude. -
暂无中文简介
- Michael J. O’Donnell has served as a director since June 1998. Mr. O’Donnell has been a member of the law firm of Morrison & Foerster LLP since 2011. Morrison & Foerster LLP is the Company’s corporate counsel and provides legal services to the Company. Mr. O’Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Previously, Mr. O’Donnell was a member of Wilson Sonsini Goodrich & Rosati. Mr. O’Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.
- Remi Barbier
-
Remi Barbier，本公司的创始人；自本公司1998年成立之时起，担任总裁、首席执行官、董事长。此前，他参与了以下公司的成立或成长：Exelixis Inc.，功能基因组学公司；ArQule, Inc.，化学公司；EnzyMed, Inc.，现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月，他担任Exelixis的首席运营官。1993-1995，他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago. - Remi Barbier，本公司的创始人；自本公司1998年成立之时起，担任总裁、首席执行官、董事长。此前，他参与了以下公司的成立或成长：Exelixis Inc.，功能基因组学公司；ArQule, Inc.，化学公司；EnzyMed, Inc.，现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月，他担任Exelixis的首席运营官。1993-1995，他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
- Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
- Nadav Friedmann
-
Nadav Friedmann，1998年起担任董事。他从2001年10月起，担任首席运营官；2004年起，担任首席医学与运营官。他是EMET Research的所有者、总裁，这是一家制药行业的咨询公司。1997-2000，他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官；1995-1997，他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995，他担任Xoma Ltd.（原Xoma Corporation）的临床研究副总裁。1980-1991，他在Johnson & Johnson （J&J）担任过各种领导职务，包括副总裁、J&J生物技术中心研究总监。此前，他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Medical Officer since 2001. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego. - Nadav Friedmann，1998年起担任董事。他从2001年10月起，担任首席运营官；2004年起，担任首席医学与运营官。他是EMET Research的所有者、总裁，这是一家制药行业的咨询公司。1997-2000，他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官；1995-1997，他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995，他担任Xoma Ltd.（原Xoma Corporation）的临床研究副总裁。1980-1991，他在Johnson & Johnson （J&J）担任过各种领导职务，包括副总裁、J&J生物技术中心研究总监。此前，他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
- Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Medical Officer since 2001. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
- Robert Z. Gussin
-
Robert Z. Gussin，2003年3月起担任董事。他在J&J 工作了26年，最后的职务是首席科学官、企业科学与技术副总裁，任期从1986年直到2000年退休。担任该职之前，他在J&J 的McNeil部门工作了12年，最后的职务是研发副总裁、科学事务副总裁。1967-1974，他在制药公司Lederle Laboratories担任过各种研究性的职务。他目前担任Duquesne University的董事、Duquesne University Pharmacy School咨询委员会成员、University of Michigan Medical School Department of Pharmacology的咨询委员会成员。他以优异成绩在Duquesne University获得了学士学位、硕士学位、博士学位，并在University of Michigan, Ann Arbor获得药理学博士学位。
Robert Z. Gussin has served as a director since March 2003. Dr. Gussin worked at Johnson & Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor. - Robert Z. Gussin，2003年3月起担任董事。他在J&J 工作了26年，最后的职务是首席科学官、企业科学与技术副总裁，任期从1986年直到2000年退休。担任该职之前，他在J&J 的McNeil部门工作了12年，最后的职务是研发副总裁、科学事务副总裁。1967-1974，他在制药公司Lederle Laboratories担任过各种研究性的职务。他目前担任Duquesne University的董事、Duquesne University Pharmacy School咨询委员会成员、University of Michigan Medical School Department of Pharmacology的咨询委员会成员。他以优异成绩在Duquesne University获得了学士学位、硕士学位、博士学位，并在University of Michigan, Ann Arbor获得药理学博士学位。
- Robert Z. Gussin has served as a director since March 2003. Dr. Gussin worked at Johnson & Johnson for 26 years, most recently as Chief Scientific Officer and Corporate Vice President, Science and Technology from 1986 through his retirement in 2000. Dr. Gussin served on the board of directors of Duquesne University and the advisory boards of the Duquesne University Pharmacy School and the University of Michigan Medical School Department of Pharmacology. Dr. Gussin received his B.S. and M.S. degrees and D.Sc. with honors from Duquesne University and his Ph.D. in Pharmacology from the University of Michigan, Ann Arbor.
- Patrick J. Scannon
-
Patrick J. Scannon，2007年起担任董事。他是XOMA的创始人之一，现任其董事。他从2006年起，担任XOMA的执行副总裁、首席生物技术官。1993-2006，他担任XOMA的首席科学与医学官。他获得了University of California, Berkeley的有机化学博士学位、Medical College of Georgia的医学博士学位。
Patrick J. Scannon has served as a director since December 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016 Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006 Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia. - Patrick J. Scannon，2007年起担任董事。他是XOMA的创始人之一，现任其董事。他从2006年起，担任XOMA的执行副总裁、首席生物技术官。1993-2006，他担任XOMA的首席科学与医学官。他获得了University of California, Berkeley的有机化学博士学位、Medical College of Georgia的医学博士学位。
- Patrick J. Scannon has served as a director since December 2007. Dr. Scannon is one of the founders of XOMA. From 2006 to 2016 Dr. Scannon was Executive Vice President, Chief Biotechnology Officer of XOMA. From 1993 to 2006 Dr. Scannon served as Chief Scientific and Medical Officer of XOMA. Dr. Scannon retired from XOMA and resigned from XOMA’s board of directors in 2016. Dr. Scannon received his Ph.D. in organic chemistry from the University of California, Berkeley and his M.D. from the Medical College of Georgia.
- Patrick J. Scannon
-
Patrick J. Scannon，他是医学博士和哲学博士。他是公司的创始人，也曾担任董事（公司成立以来）。他于2011年2月被任命为执行副总裁兼首席科学官。此前，他曾担任执行副总裁兼首席医疗官（始于2009年3月），也曾担任执行副总裁兼首席技术官（从2006年5月到2009年3月）、首席科学官兼首席医疗官（从1993年3月到2006年5月）、高级副总裁（从1999年5月到2006年5月）、负责科学和医学事务的副主席（从1992年4月到1993年3月）、总裁（从公司创立到1992年4月）。他于2007年被邀请加入新成立的国家生物防御科学委员会（National Biodefense Science Board），负责向卫生和人类服务部部长报告。他也曾任职 the Defense Advanced Research Projects Agency（DARPA）国防科学研究委员会，以及国防部（the Department of Defense）的威胁压制咨询委员会。他于2007年被任命为Pain Therapeutics公司（一家生物制药公司）的董事会。2007年起担任董事。他是XOMA的创始人之一，现任其董事。他从2006年起，担任XOMA的执行副总裁、首席生物技术官。1993-2006，他担任XOMA的首席科学与医学官。从1979年到1981年，他曾担任the Letterman Army Institute of Research（位于旧金山）的临床研究科学家。他是内科医生，持有加州大学伯克利分校（the University of California, Berkeley）的有机化学博士学位，以及 the Medical College of Georgia的医学博士学位。
Patrick J. Scannon is one of the Company's founders and has served as a director since its formation. Dr. Scannon became Executive Vice President and Chief Scientific Officer in February of 2011. Previously he was Executive Vice President and Chief Medical Officer beginning in March of 2009 and served as Executive Vice President and Chief Biotechnology Officer from May of 2006 until March of 2009 Chief Scientific and Medical Officer from March of 1993 until May of 2006 Senior Vice President from May of 1999 to May of 2006 Vice Chairman, Scientific and Medical Affairs from April of 1992 to March of 1993 and President from the Company's formation until April of 1992. In 2007 Dr. Scannon was invited to join the newly formed National Biodefense Science Board, reporting to the Secretary of the Department of Health and Human Services. He also served on the Defense Sciences Research Council for the Defense Advanced Research Projects Agency and on the Threat Reduction Advisory Committee for the Department of Defense. In 2007 he was appointed to the Board of Directors of Pain Therapeutics, Inc., a biopharmaceutical company. From 1979 until 1981 Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco. A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an M.D. from the Medical College of Georgia. - Patrick J. Scannon，他是医学博士和哲学博士。他是公司的创始人，也曾担任董事（公司成立以来）。他于2011年2月被任命为执行副总裁兼首席科学官。此前，他曾担任执行副总裁兼首席医疗官（始于2009年3月），也曾担任执行副总裁兼首席技术官（从2006年5月到2009年3月）、首席科学官兼首席医疗官（从1993年3月到2006年5月）、高级副总裁（从1999年5月到2006年5月）、负责科学和医学事务的副主席（从1992年4月到1993年3月）、总裁（从公司创立到1992年4月）。他于2007年被邀请加入新成立的国家生物防御科学委员会（National Biodefense Science Board），负责向卫生和人类服务部部长报告。他也曾任职 the Defense Advanced Research Projects Agency（DARPA）国防科学研究委员会，以及国防部（the Department of Defense）的威胁压制咨询委员会。他于2007年被任命为Pain Therapeutics公司（一家生物制药公司）的董事会。2007年起担任董事。他是XOMA的创始人之一，现任其董事。他从2006年起，担任XOMA的执行副总裁、首席生物技术官。1993-2006，他担任XOMA的首席科学与医学官。从1979年到1981年，他曾担任the Letterman Army Institute of Research（位于旧金山）的临床研究科学家。他是内科医生，持有加州大学伯克利分校（the University of California, Berkeley）的有机化学博士学位，以及 the Medical College of Georgia的医学博士学位。
- Patrick J. Scannon is one of the Company's founders and has served as a director since its formation. Dr. Scannon became Executive Vice President and Chief Scientific Officer in February of 2011. Previously he was Executive Vice President and Chief Medical Officer beginning in March of 2009 and served as Executive Vice President and Chief Biotechnology Officer from May of 2006 until March of 2009 Chief Scientific and Medical Officer from March of 1993 until May of 2006 Senior Vice President from May of 1999 to May of 2006 Vice Chairman, Scientific and Medical Affairs from April of 1992 to March of 1993 and President from the Company's formation until April of 1992. In 2007 Dr. Scannon was invited to join the newly formed National Biodefense Science Board, reporting to the Secretary of the Department of Health and Human Services. He also served on the Defense Sciences Research Council for the Defense Advanced Research Projects Agency and on the Threat Reduction Advisory Committee for the Department of Defense. In 2007 he was appointed to the Board of Directors of Pain Therapeutics, Inc., a biopharmaceutical company. From 1979 until 1981 Dr. Scannon was a clinical research scientist at the Letterman Army Institute of Research in San Francisco. A Board-certified internist, Dr. Scannon holds a Ph.D. in organic chemistry from the University of California, Berkeley and an M.D. from the Medical College of Georgia.
- Michael J. O'donnell
-
Michael J. O'donnell，1998年起担任董事。他从2011年1月起，担任律师事务所Morrison & Foerster, LLP的合伙人。1993年至2011年1月，他是律师事务所Wilson Sonsini Goodrich & Rosati, Professional Corporation的合伙人。orrison & Foerster, LLP是本公司的企业法律顾问，为本公司提供法律咨询服务。目前，他是许多上市及私营的生物制药与生命科学公司的企业法律顾问。他以优异的成绩获得Harvard University的法律博士学位，并以优等生的荣誉获得Bucknell University的学士学位。
Michael J. O'Donnell, Esq. has served as a director since 1998. Mr. O'Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011 Mr. O'Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation. Morrison & Foerster, LLP is the Company's corporate counsel and provides legal services to the Company. Mr. O'Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O'Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude. - Michael J. O'donnell，1998年起担任董事。他从2011年1月起，担任律师事务所Morrison & Foerster, LLP的合伙人。1993年至2011年1月，他是律师事务所Wilson Sonsini Goodrich & Rosati, Professional Corporation的合伙人。orrison & Foerster, LLP是本公司的企业法律顾问，为本公司提供法律咨询服务。目前，他是许多上市及私营的生物制药与生命科学公司的企业法律顾问。他以优异的成绩获得Harvard University的法律博士学位，并以优等生的荣誉获得Bucknell University的学士学位。
- Michael J. O'Donnell, Esq. has served as a director since 1998. Mr. O'Donnell has been a member of the law firm of Morrison & Foerster, LLP since January 2011. From 1993 to January 2011 Mr. O'Donnell was a member of the law firm of Wilson Sonsini Goodrich & Rosati, Professional Corporation. Morrison & Foerster, LLP is the Company's corporate counsel and provides legal services to the Company. Mr. O'Donnell serves as corporate counsel to numerous public and private biopharmaceutical and life sciences companies. Mr. O'Donnell received his J.D., cum laude, from Harvard University and his B.A. from Bucknell University, summa cum laude.
- Sanford R. Robertson
-
Sanford R. Robertson，2003年10月担任董事长一职。他是范斯高合伙企业（技术收购基金公司）的首要合伙人。在创立公司之前，2000年1月，他是罗伯森和史蒂芬公司（一家技术投资公司）的创立者和主席。他已经在对家技术公司担任过技术投资人和咨询顾问，他还是罗伯特、科尔曼、希柏和维塞尔公司（后来重命名为蒙哥马利证券公司）的创立者。目前，他人三家上市公司（杜比研究所、疼痛治疗公司和PRX公司）的董事长。在过去五年里，他还是嘉信慈善基金董事长，拥有密歇根大学的工商管理学士和硕士学位。
Sanford R. Robertson has served as a Director since October 2003. Mr. Robertson has been an active technology investor and advisor to technology companies. He has been a principal of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank. Mr. Robertson was also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities, another prominent technology investment bank. Mr. Robertson currently serves on the Board of Directors of Cassava Sciences, Inc. and, within the past five years, also served on the Board of Directors of RPX Corporation. Mr. Robertson received his B.B.A. and M.B.A. with distinction from the University of Michigan. - Sanford R. Robertson，2003年10月担任董事长一职。他是范斯高合伙企业（技术收购基金公司）的首要合伙人。在创立公司之前，2000年1月，他是罗伯森和史蒂芬公司（一家技术投资公司）的创立者和主席。他已经在对家技术公司担任过技术投资人和咨询顾问，他还是罗伯特、科尔曼、希柏和维塞尔公司（后来重命名为蒙哥马利证券公司）的创立者。目前，他人三家上市公司（杜比研究所、疼痛治疗公司和PRX公司）的董事长。在过去五年里，他还是嘉信慈善基金董事长，拥有密歇根大学的工商管理学士和硕士学位。
- Sanford R. Robertson has served as a Director since October 2003. Mr. Robertson has been an active technology investor and advisor to technology companies. He has been a principal of Francisco Partners, a technology buyout fund, since 1999. Prior to founding Francisco Partners, Mr. Robertson was the founder and chairman of Robertson, Stephens & Company, a technology investment bank. Mr. Robertson was also the founder of Robertson, Colman, Siebel & Weisel, later renamed Montgomery Securities, another prominent technology investment bank. Mr. Robertson currently serves on the Board of Directors of Cassava Sciences, Inc. and, within the past five years, also served on the Board of Directors of RPX Corporation. Mr. Robertson received his B.B.A. and M.B.A. with distinction from the University of Michigan.
高管简历
中英对照 | 中文 | 英文- James W. Kupiec
James W.Kupiec自2021年1月起担任首席临床开发官。Kupiec博士在辉瑞，赛诺菲和Ciba-Geigy拥有30年的药物开发经验后加入公司。Kupiec博士此前曾担任帕金森氏症的副总裁，全球临床领导者，以及位于马萨诸塞州剑桥市的辉瑞公司神经科学研究部门的临床主管。他于2000年加入Pfizer公司，此前曾任职Sanofi公司7年，以及Ciba-Geigy Pharmaceuticals公司2年。在Pfizer的17年职业生涯中，Kupiec博士承担了广泛的治理、业务发展、联盟和领导责任。Kupiec博士在石溪大学获得生物化学学士学位，并在阿尔伯特·爱因斯坦医学院获得医学博士学位。他在罗切斯特大学医学院Strong Memorial Hospital完成了住院医师培训，并获得了美国内科委员会的认证。在过渡到制药行业之前，他曾担任许多临床试验的研究员。
James W. Kupiec has served as Chief Clinical Development Officer since January 2021. Dr. Kupiec joined the Company after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as Vice President, Global Clinical Leader for Parkinson’s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before transitioning to the pharmaceutical industry.- James W.Kupiec自2021年1月起担任首席临床开发官。Kupiec博士在辉瑞，赛诺菲和Ciba-Geigy拥有30年的药物开发经验后加入公司。Kupiec博士此前曾担任帕金森氏症的副总裁，全球临床领导者，以及位于马萨诸塞州剑桥市的辉瑞公司神经科学研究部门的临床主管。他于2000年加入Pfizer公司，此前曾任职Sanofi公司7年，以及Ciba-Geigy Pharmaceuticals公司2年。在Pfizer的17年职业生涯中，Kupiec博士承担了广泛的治理、业务发展、联盟和领导责任。Kupiec博士在石溪大学获得生物化学学士学位，并在阿尔伯特·爱因斯坦医学院获得医学博士学位。他在罗切斯特大学医学院Strong Memorial Hospital完成了住院医师培训，并获得了美国内科委员会的认证。在过渡到制药行业之前，他曾担任许多临床试验的研究员。
- James W. Kupiec has served as Chief Clinical Development Officer since January 2021. Dr. Kupiec joined the Company after three decades of drug development experience at Pfizer, Sanofi and Ciba-Geigy. Dr. Kupiec previously served as Vice President, Global Clinical Leader for Parkinson’s Disease and Clinical Head of the Neuroscience Research Unit for Pfizer, Inc., in Cambridge, MA. He joined Pfizer in 2000 after seven years with Sanofi, and two years with Ciba-Geigy Pharmaceuticals. During his 17-year career at Pfizer, Dr. Kupiec had extensive governance, business development, alliance and leadership responsibilities. Dr. Kupiec earned his BS with Honors in Biochemistry at Stony Brook University and his MD from the Albert Einstein College of Medicine. He completed his residency training at the Strong Memorial Hospital, University of Rochester School of Medicine, and is certified by the American Board of Internal Medicine. He served as an investigator on many clinical trials before transitioning to the pharmaceutical industry.
- Remi Barbier
Remi Barbier，本公司的创始人；自本公司1998年成立之时起，担任总裁、首席执行官、董事长。此前，他参与了以下公司的成立或成长：Exelixis Inc.，功能基因组学公司；ArQule, Inc.，化学公司；EnzyMed, Inc.，现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月，他担任Exelixis的首席运营官。1993-1995，他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.- Remi Barbier，本公司的创始人；自本公司1998年成立之时起，担任总裁、首席执行官、董事长。此前，他参与了以下公司的成立或成长：Exelixis Inc.，功能基因组学公司；ArQule, Inc.，化学公司；EnzyMed, Inc.，现为化学公司Albany Molecular Research所拥有。1996年1月至1998年5月，他担任Exelixis的首席运营官。1993-1995，他担任生物技术公司Xoma Corporation的企业发展副总裁、临床项目经理。他目前是Carnegie Institute of Washington的受托人、California Institute for Quantitative Biosciences的咨询委员会成员。他获得了Oberlin College的学士学位、University of Chicago的工商管理硕士学位。
- Remi Barbier, the Company’s founder, has served as President, Chief Executive Officer and Chairman of the Board of Directors since the Company’s inception in May 1998. Prior to that time, Mr. Barbier helped in the growth or founding of Exelixis Inc. and ArQule, Inc., both publicly-traded drug development companies, and EnzyMed, Inc., a chemistry company sold to Albany Molecular Research, Inc. Mr. Barbier is a trustee emeritus of the Carnegie Institute of Washington and the Santa Fe Institute and is on the Advisory Board of the University of California Institute for Quantitative Biosciences and BioVentures LLC, a life science incubator at the University of Arkansas for Medical Sciences. Mr. Barbier received his B.A. from Oberlin College and his M.B.A. from the University of Chicago.
- Nadav Friedmann
Nadav Friedmann，1998年起担任董事。他从2001年10月起，担任首席运营官；2004年起，担任首席医学与运营官。他是EMET Research的所有者、总裁，这是一家制药行业的咨询公司。1997-2000，他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官；1995-1997，他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995，他担任Xoma Ltd.（原Xoma Corporation）的临床研究副总裁。1980-1991，他在Johnson & Johnson （J&J）担任过各种领导职务，包括副总裁、J&J生物技术中心研究总监。此前，他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Medical Officer since 2001. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.- Nadav Friedmann，1998年起担任董事。他从2001年10月起，担任首席运营官；2004年起，担任首席医学与运营官。他是EMET Research的所有者、总裁，这是一家制药行业的咨询公司。1997-2000，他担任制药公司Daiichi Pharmaceutical Corporation的总裁、首席执行官；1995-1997，他是东京Daiichi Pharmaceutical的董事会顾问。1992-1995，他担任Xoma Ltd.（原Xoma Corporation）的临床研究副总裁。1980-1991，他在Johnson & Johnson （J&J）担任过各种领导职务，包括副总裁、J&J生物技术中心研究总监。此前，他是Abbott Laboratories的医学总监。他获得了Albert Einstein College of Medicine的医学博士学位、University of California, San Diego的生物化学博士学位。
- Nadav Friedmann has served as a director since September 1998. Dr. Friedmann has served as Chief Medical Officer since 2001. Dr. Friedmann was previously President and CEO of Daiichi Pharmaceutical Corporation. Dr. Friedmann has served as Vice President, Clinical Research at Xoma Corporation, and held various senior leadership positions with Johnson & Johnson, including Head of its Biotechnology Research Center. Dr. Friedmann received his M.D. from the Albert Einstein College of Medicine and his Ph.D. in Biochemistry from the University of California, San Diego.
- Eric J. Schoen
Eric J. Schoen，他于2010年7月加入公司，担任我们公司的总会计师。他于2013年5月28日被任命为财务副总裁，并一直担任我们的首席会计官（2011年10月以来）。加入公司之前，他曾担任Borland Software公司（一个公开上市的软件开发公司）的收入总会计师（从2007年到2010年）。从2000年到2007年，他担任Trilogy Enterprises公司、Momentum Software公司和Alticast公司的公司总会计师和财务董事。他也曾任职普华永道（PricewaterhouseCoopers）9年，最近担任审计及咨询、交易服务和全球资本市场实践经理。他获得了Santa Clara University的金融学士学位。
Eric J. Schoen has served as Chief Financial Officer since October 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspria Women’s Health Inc. formerly Vermillion, Inc., a publicly-held women’s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.- Eric J. Schoen，他于2010年7月加入公司，担任我们公司的总会计师。他于2013年5月28日被任命为财务副总裁，并一直担任我们的首席会计官（2011年10月以来）。加入公司之前，他曾担任Borland Software公司（一个公开上市的软件开发公司）的收入总会计师（从2007年到2010年）。从2000年到2007年，他担任Trilogy Enterprises公司、Momentum Software公司和Alticast公司的公司总会计师和财务董事。他也曾任职普华永道（PricewaterhouseCoopers）9年，最近担任审计及咨询、交易服务和全球资本市场实践经理。他获得了Santa Clara University的金融学士学位。
- Eric J. Schoen has served as Chief Financial Officer since October 2018. Prior to joining the Company, Mr. Schoen served in numerous financial leadership roles. Most recently, he served as Vice President, Senior Vice President, Finance and Chief Accounting Officer of Aspria Women’s Health Inc. formerly Vermillion, Inc., a publicly-held women’s health company, from 2011 to 2017. Mr. Schoen also began his career and spent nine years with PricewaterhouseCoopers in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his B.S. in Finance from Santa Clara University.